Daily Sepsis Research Analysis
Analyzed 22 papers and selected 3 impactful papers.
Summary
Analyzed 22 papers and selected 3 impactful articles.
Selected Articles
1. Deltex E3 ubiquitin ligase 2 prevents sepsis-induced myocardial injury through degrading TfR1 via promoting K27-linked ubiquitination.
DTX2 protects the septic heart by promoting K27-linked ubiquitination and degradation of TfR1, thereby limiting iron-driven ferroptosis. Loss of DTX2 exacerbates, while cardiac overexpression ameliorates, sepsis-induced myocardial injury across in vivo and in vitro systems.
Impact: Identifies a precise ubiquitin signaling mechanism linking iron metabolism to septic cardiomyopathy and validates ferroptosis as a tractable target. Provides multiple causal levers (DTX2, TfR1, ferroptosis inhibitors) for translational development.
Clinical Implications: Suggests that enhancing DTX2 activity or targeting TfR1/ferroptosis could mitigate septic cardiomyopathy. Supports biomarker development (DTX2/TfR1) and rationale for testing ferroptosis inhibitors in sepsis-induced cardiac dysfunction.
Key Findings
- DTX2 expression is upregulated in septic patients, mouse models, and LPS-stimulated cardiomyocytes.
- Dtx2 deficiency aggravates myocardial hypertrophy, fibrosis, ferroptosis, and mitochondrial dysfunction in sepsis.
- DTX2 promotes K27-linked ubiquitination of TfR1 at lysine 39, facilitating its degradation and regulating iron metabolism.
- Ferroptosis inhibition or TfR1 silencing rescues cardiac injury phenotypes caused by Dtx2 deficiency.
Methodological Strengths
- Convergent evidence across human samples, mouse models, and cell systems with gain- and loss-of-function.
- Mechanistic dissection including domain mapping, site-specific ubiquitination, and functional rescue experiments.
Limitations
- Translational applicability not yet demonstrated in clinical trials; no pharmacologic DTX2 modulators tested.
- Sepsis models (e.g., LPS challenge) may not capture full clinical heterogeneity.
Future Directions: Develop small-molecule or gene therapy approaches to enhance DTX2 or modulate TfR1; test ferroptosis inhibitors in sepsis cardiomyopathy models with clinically relevant endpoints.
Sepsis, a life-threatening systemic inflammatory condition, frequently leads to myocardial injury-a complication for which current therapeutic strategies demonstrate limited efficacy. Here, we explored the potential role and therapeutic implications of Deltex E3 ubiquitin ligase 2 (DTX2) in sepsis-induced myocardial injury. Our results demonstrated that DTX2 expression was significantly upregulated in septic patients, mice models, and lipopolysaccharide (LPS)-stimulated cardiomyocytes. Notably, Dtx2 deficiency markedly aggravated sepsis-induced myocardial hypertrophy, fibrosis, ferroptosis, and mitochondrial dysfunction. In contrast, cardiac-specific overexpression of Dtx2 improved cardiac function in vivo, highlighting its protective role in septic cardiomyopathy. Mechanistically, DTX2 was found to directly interact with transferrin receptor 1 (TfR1) through its DTC domain, mediating K27-linked ubiquitination at lysine 39, which facilitated TfR1 degradation and regulated iron metabolism. Importantly, pharmacological inhibition of ferroptosis counteracted the detrimental effects of Dtx2 deficiency in both LPS-challenged cells and mice. Moreover, genetic silencing of TfR1 considerably suppressed ferroptosis and ameliorated myocardial injury in Dtx2 knockout septic mice. The findings indicate that DTX2 exerts protective effects against abnormal iron accumulation and ferroptosis, thereby alleviating myocardial injury induced by sepsis. These insights could have therapeutic implications for patients with reduced DTX2 expression.
2. Uncovering the Untapped Potential of Furosemide in Sepsis: Real-World Evidence on Coagulopathy and Organ Outcomes.
In a matched national cohort of 9,934 septic adults, furosemide use was associated with markedly lower DIC risk and reduced cardiac, respiratory, and renal failures, with benefits not observed for other diuretics. Findings support a unique mechanism possibly linked to NKCC1-modulated antioxidant/anti-inflammatory pathways.
Impact: Generates a strong, biologically plausible hypothesis for repurposing an inexpensive, widely available drug to mitigate sepsis coagulopathy and organ failure, supported by active comparator analyses.
Clinical Implications: While not practice-changing yet, clinicians may consider the potential adjunctive role of furosemide when managing fluid balance in sepsis; randomized trials should assess timing, dosing, and patient selection.
Key Findings
- Furosemide use was associated with lower DIC risk (aHR 0.196, 95% CI 0.067-0.516).
- Protective associations for cardiac, respiratory, and acute renal failure and lower all-cause mortality were observed.
- Active comparator analysis indicated organ protection was specific to furosemide and not seen with other diuretics.
Methodological Strengths
- Large population-based matched cohort with active comparator design.
- Robust multivariable Cox models with durability testing to 12 months.
Limitations
- Observational design risks residual confounding and confounding by indication.
- Administrative data may lack granularity on dosing, timing, and clinical severity measures.
Future Directions: Conduct randomized controlled trials to test furosemide as an adjunct in sepsis, defining optimal timing, dosing, and target phenotypes; mechanistic studies to confirm NKCC1-related pathways in humans.
BACKGROUND: Sepsis-related coagulopathy is a major driver of organ failure and mortality, yet effective adjuncts remain limited. We therefore examined whether early furosemide use is associated with reduced coagulopathy and improved organ outcomes in real-world practice. METHODS: Using Taiwan's National Health Insurance Research Database (2000-2013), we assembled a population-based matched cohort of 9,934 adults with incident sepsis. Exposure was receipt of furosemide during the index hospitalization; comparators were other diuretics (e.g., acetazolamide, hydrochlorothiazide, spironolactone). The primary outcome was disseminated intravascular coagulation (DIC); secondary outcomes included transfusion, organ failures (cardiac, respiratory, renal, hepatic), and all-cause mortality. Multivariable Cox models estimated adjusted hazard ratios (aHRs). RESULTS: In the primary analysis (3-month follow-up), furosemide use was associated with a lower risk of DIC (aHR 0.196, 95% CI 0.067-0.516, P < 0.001) and transfusion. These associations remained durable in the exploratory 12-month analysis. Significant protective associations were also observed for cardiac, respiratory, and acute renal failure, alongside lower all-cause mortality. Crucially, active comparator analysis revealed that while associations with lower mortality were shared across diuretic classes, the protective associations with organ failure were specific to furosemide and not observed with other diuretics, supporting a distinct pharmacological effect beyond general diuresis. CONCLUSION: Real-world evidence suggests that furosemide use is associated with reduced sepsis-related coagulopathy and favorable organ outcomes. These findings generate a biologically plausible hypothesis consistent with Na +-K +-2Cl - cotransporter 1 (NKCC1)-related antioxidant and anti-inflammatory pathways observed in preclinical models, warranting confirmation in prospective trials.
3. Impact of prehospital antibiotic therapy differs depending on septic shock origin.
In a nationwide target-trial emulation of 530 septic shock patients treated by prehospital MICUs, prehospital antibiotic administration was associated with lower 30-day mortality (RR 0.64). Effects varied by presumed source, with signals in pulmonary, urinary, and unknown origins.
Impact: Directly informs prehospital protocols by quantifying the survival association of early antibiotics in septic shock using rigorous causal emulation methods.
Clinical Implications: Supports implementing protocols for field antibiotics in suspected septic shock, with attention to source-specific effectiveness and antimicrobial stewardship; randomized trials are warranted.
Key Findings
- Prehospital antibiotics were associated with reduced 30-day mortality in septic shock (RR 0.64, 95% CI 0.41-0.97).
- Effect heterogeneity by source with signals in pulmonary, urinary, and unknown origins.
- Sepsis sources in the prehospital setting were mainly pulmonary (43%), digestive (25%), and urinary (17%).
Methodological Strengths
- Target trial emulation with inverse probability of treatment weighting to reduce confounding.
- Nationwide multicenter cohort reflecting real-world prehospital MICU practice.
Limitations
- Observational design with potential residual confounding and misclassification of infection source.
- Antibiotic selection, dosing, and exact timing were not randomized and may vary by local protocols.
Future Directions: Prospective randomized trials of prehospital antibiotics in septic shock with stratification by suspected source; evaluation of bundle components and optimal antibiotic regimens.
BACKGROUND: International guidelines recommend early a bundle of care to reduce sepsis mortality. Among bundle of care, antibiotic therapy is all the additionally effective when early initiated, especially for the sicker patients, i.e., those with septic shock, for whom it should be started within the first hour. This study aims to examine the impact of prehospital antibiotics administration on 30-day mortality in patients with septic shock, as defined by Sepsis-2, cared for by a prehospital mobile intensive care unit (MICU). METHODS: We performed a nationwide observational cohort study in France using data from May 2016 to December 2021 including septic shock patients admitted to ICU after receiving prehospital care from a MICU. An emulate retrospective randomized controlled trial using a weighted Cox proportional hazards model was conducted to compare the efficacy of prehospital antibiotic administration versus no prehospital antibiotic administration on 30-day mortality. A secondary analysis assessed the association between prehospital antibiotic administration and 30-day mortality according to presumed septic shock origin. RESULTS: Among the 530 patients analyzed, 341 (64%) were males and the mean age was 70 ± 15 years. The 30-day mortality was 31%. The presumed origins of sepsis in the prehospital setting were primarily pulmonary, digestive, and urinary, with respective percentages of 43%, 25%, and 17%, respectively. One-hundred and thirty-two patients (25%) received prehospital antibiotic therapy, a 3rd generation cephalosporin for 98 patients (18%). The inverse probability of treatment weighting analysis emulating the target trial revealed that prehospital antibiotic administration was associated with a lower risk of 30-day mortality compared with no prehospital antibiotic administration: RR = 0.64, 95%CI [0.41-0.97]. The weighted logistic regression model showed a significant association between 30-day mortality and prehospital antibiotic administration for pulmonary origin: RRa = 0.80 [0.86-0.93], urinary origin: RRa = 0.89 [0.80-0.98], and unknown origin: RRa = 0.94 [0.86-0.99]. CONCLUSION: The prehospital antibiotics administration is associated with a reduced risk of 30-day mortality among patients suffering from septic shock cared for by a prehospital MICU. The prehospital antibiotic treatment effect differs according to septic shock origin. However, prospective studies are necessary to validate these preliminary findings and to assess the supplementary effects of the bundle of care components.